Development of universal influenza vaccines based on influenza virus M and NP genes

Abstract

The matrix protein (M1, M2) and nucleoprotein (NP) of influenza viruses have highly conserved sequences, and they become the major target antigens of current UIV studies.

Protection against influenza H7N9 virus challenge with a recombinant NP–M1–HSP60 protein vaccine construct in BALB/c mice

“…Previous studies have shown that NP-and M1-based immunization protect mice against lethal challenge with influenza virus (Boyd et al, 2012;Donnelly et al, 1997;Zheng et al, 2013). However, most reported NP-and M1-based vaccines are DNA- (Antrobus et al, 2014;Donnelly et al, 1997;Ohba et al, 2007;Zhirnov et al, 2007) or viral-skeleton-based (Antrobus et al, 2012;Choi et al, 2012;Lillie et al, 2012;Price et al, 2010;Quan et al, 2012), and other papers indicated that NP-based vaccines fail to provide complete protection against influenza virus (Chen et al, 1998;Jamali et al, 2010;Krammer and Palese, 2014;Lawson et al, 1994).…”

Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases

“…These can be delivered as protein, peptide-carrier conjugate, VLP, DNA plasmid or by viral vectors [68]. However, also other relatively conserved influenza virus proteins might be considered for the induction of cross-reactive T cell responses, like the polymerase subunits (PA, PB1 and PB2).…”

Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant

“…Moreover, recombinant protein vaccines have excellent safety, and can induce adequate antibody levels in a population vaccination, and therefore have become an important direction of influenza vaccine development at present. 9 However, if a new pandemic influenza virus breaks out, vaccination with a recombinant protein vaccine seems to be insufficient. Therefore, to further improve effectiveness of UIV, researchers tried to achieve the desired goals through combined use of multiple target antigens.…”